The effect of a high-fat meal on the pharmacodynamics of a model lipophilic compound that binds extensively to triglyceride-rich lipoproteins

International Journal of Pharmaceutics

Volumn 333, Issue 1-2, 2007, Pages 1-4

  Gershkovich, Pavel ^a   Shtainer, Daniel ^a   Hoffman, Amnon ^a  

^a Faculty of Medicine   (Israel)

Author keywords

Chylomicrons; Food drug interaction; Lipophilic drugs; Neurotoxicity; Pharmacodynamics; Pharmacokinetics

Indexed keywords

ARACHIS OIL; CHLORPHENOTANE; CHYLOMICRON; DIAZEPAM; TRIACYLGLYCEROL; WATER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG DISTRIBUTION; FOOD DRUG INTERACTION; HYPERLIPIDEMIA; LIPID DIET; MALE; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT; TREMOR; TRIACYLGLYCEROL BLOOD LEVEL;

ADMINISTRATION, ORAL; ANIMALS; BRAIN; CHYLOMICRONS; DDT; DIETARY FATS; FACIAL MUSCLES; FOOD-DRUG INTERACTIONS; HYPERLIPIDEMIAS; INFUSIONS, INTRAVENOUS; MALE; PLANT OILS; POSTPRANDIAL PERIOD; PROTEIN BINDING; RATS; RATS, WISTAR; TREMOR; TRIGLYCERIDES;

EID: 33847100504     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2007.01.012     Document Type: Article

References (23)

1. Black W.D., and Ecobichon D.J. A pharmacodynamic study of DDT in rabbits following acute intravenous administration. Can. J. Physiol. Pharmacol. 49 (1971) 45-52
2. Brocks D.R., Ala S., and Aliabadi H.M. The effect of increased lipoprotein levels on the pharmacokinetics of cyclosporine A in the laboratory rat. Biopharm. Drug Dispos. 27 (2006) 7-16
3. Brocks D.R., and Wasan K.M. The influence of lipids on stereoselective pharmacokinetics of halofantrine: Important implications in food-effect studies involving drugs that bind to lipoproteins. J. Pharm. Sci. 91 (2002) 1817-1826
4. Ecobichon D.J., and Saschenbrecker P.W. Pharmacodynamic study of DDT in cockerels. Can. J. Physiol. Pharmacol. 46 (1968) 785-794
5. Eder H.A. The effect of diet on the transport of probucol in monkeys. Artery 10 (1982) 105-107
6. Gershkovich P., and Hoffman A. Uptake of lipophilic drugs by plasma derived isolated chylomicrons: linear correlation with intestinal lymphatic bioavailability. Eur. J. Pharm. Sci. 26 (2005) 394-404
7. Henderson G.L., and Woolley D.E. Mechanisms of neurotoxic action of 1,1,1-trichloro-2,2-bis(p-chlorophenyl)ethane (DDT) in immature and adult rats. J. Pharmacol. Exp. Ther. 175 (1970) 60-68
8. Hisaoka M., and Levy G. Kinetics of drug action in disease states. XIII. Effect of dialyzable component(s) of uremic blood on phenobarbital concentrations in rats at onset of loss of righting reflex. J. Pharmacol. Exp. Ther. 234 (1985) 180-183
9. Hoffman A., and Levy G. Kinetics of drug action in disease states. XXIX. Effect of experimental nephrotic syndrome on the pharmacodynamics of heptabarbital: implications of severe hypoalbuminemia. J. Pharmacol. Exp. Ther. 249 (1989) 117-122
10. Hoffman A., and Levy G. Kinetics of drug action in disease states. XLI. Effect of adrenalectomy on the hypnotic activity of phenobarbital, the neurotoxicity of theophylline and pain sensitivity in rats. J. Pharmacol. Exp. Ther. 264 (1993) 859-862
11. Humberstone A.J., Cowman A.F., Horton J., and Charman W.N. Effect of altered serum lipid concentrations on the IC50 of halofantrine against Plasmodium falciparum. J. Pharm. Sci. 87 (1998) 256-258
12. Humberstone A.J., Porter C.J., Edwards G.A., and Charman W.N. Association of halofantrine with postprandially derived plasma lipoproteins decreases its clearance relative to administration in the fasted state. J. Pharm. Sci. 87 (1998) 936-942
13. McIntosh M.P., Batey A.J., Coker S.J., Porter C.J., and Charman W.N. Evaluation of the impact of altered lipoprotein binding conditions on halofantrine induced QTc interval prolongation in an anaesthetized rabbit model. J. Pharm. Pharmacol. 56 (2004) 69-77
14. McIntosh M.P., Charman W.N., Campbell M., and Porter C.J. Influence of physicochemical properties on the patterns of association of a series of aliphatic esters of halofantrine with plasma lipoproteins. J. Control. Rel. 95 (2004) 275-289
15. Procyshyn R.M., Ho T., and Wasan K.M. The effects of competitive displacement on haloperidol's plasma distribution in normolipidemic and hyperlipidemic plasma. Drug Dev. Ind. Pharm. 31 (2005) 901-905
16. Ramirez M., Amate L., and Gil A. Absorption and distribution of dietary fatty acids from different sources. Early Hum. Dev. 65 (2001) S95-S101
17. Ramzan I.M., and Levy G. Kinetics of drug action in disease states. XIV. Effect of infusion rate on pentylenetetrazol concentrations in serum, brain and cerebrospinal fluid of rats at onset of convulsions. J. Pharmacol. Exp. Ther. 234 (1985) 624-628
18. Shayeganpour A., Jun A.S., and Brocks D.R. Pharmacokinetics of Amiodarone in hyperlipidemic and simulated high fat-meal rat models. Biopharm. Drug Dispos. 26 (2005) 249-257
19. Thomson A.B., Keelanm M., Gargm M.L., and Clandinin M.T. Intestinal aspects of lipid absorption: in review. Can. J. Physiol. Pharmacol. 67 (1989) 179-191
20. Wasan K.M. Modifications in plasma lipoprotein concentration and lipid composition regulate the biological activity of hydrophobic drugs. J. Pharmacol. Toxicol. Meth. 36 (1996) 1-11
21. Wasan K.M., and Cassidy S.M. Role of plasma lipoproteins in modifying the biological activity of hydrophobic drugs. J. Pharm. Sci. 87 (1998) 411-424
22. Wasan K.M., Ramaswamy M., Kwong M., and Boulanger K.D. Role of plasma lipoproteins in modifying the toxic effects of water-insoluble drugs: studies with cyclosporine A. AAPS PharmSci 4 (2002) E30
23. Wasan K.M., Wong J.C., Corr T., and Pritchard S. Role of plasma lipids and lipoproteins in predicting amphotericin B-induced nephrotoxicity in pediatric oncology patients. Cancer Chemother. Pharmacol. 57 (2006) 120-124